贝瑞基因测序技术取得新突破,临床大规模应用时代即将到来

Author: Jian Jun know

Health Bureau

On July 7th, Berry's "Technology for the Future Unlimited" product launch conference was held in Beijing, and announced that the scope of its NextSeq CN500 gene sequencer has been changed, becoming a medical institution that can be landed, and can directly carry out large-scale clinical genes. Detected NGS (next generation sequencing) universal platform.

It is understood that the scope of the change of the NextSeq CN500 gene sequencer is for human DNA sequencing (DNA) sequencing to detect gene sequences, which may lead to disease or susceptibility. The instrument can be used clinically in conjunction with the in vitro diagnostic reagents approved by the National Drug Administration and the random software associated with the instrument, and is not used for human genome sequencing or de novo sequencing.

9ea62c736a9c41759d01b66ce755eb68

▲Berry Gene Chairman Gao Yang

“Compared with research, clinical applications have more unique requirements for gene sequencers.” Gao Yang, chairman of Berry Gene, explained that due to the characteristics of clinical scenes, genetic sequencers only have simple operation, large throughput, and high data quality. When the cost of detection is low, it can be adopted by medical institutions on a large scale. This is why there are many genetic sequencers on the market, but few are actually accepted by frontline medical institutions.

According to the Knowledge Bureau, the scope of application of the NextSeq CN500 has been greatly expanded, which means that clinical genetic testing has entered more disease fields across NIPT. What is more worthy of expectation is that this platform can be used in clinical, scientific research, and multi-disciplinary fields in the future. In terms of bringing great social and economic value to society and families. This is the target market for Berry's genes.

xx自2015年获批后,已进入100多家医院,正常开展检测工作。这个数字使Berry Gene成为行业的领导者,充分展示了市场对音序器的高度认可并积累了良好的市场。口口相传。贝瑞的2018年度报告显示,其设备销售收入超过7500万元,占营业收入的5.23%以上。

NextSeq CN500为Berry开发多种疾病领域(包括肿瘤)的临床检测试剂盒提供了高质量的NGS通用平台,为临床实践中基因检测的发展提供了坚实的工具基础。同时,它还为Berry基因提供了利用测序仪作为进一步开放基因检测试剂盒市场的切入点的机会。

高阳说,整个产业链布局是Berry Gene的发展战略。 NextSeq CN500的扩容获得批准,这加强了Berry在产业链上游建立基因检测平台的目标,并提前规划了大型泛市场。为晚期肿瘤提供临床检测服务,加快肿瘤早期诊断和早期筛查的研究和开发,加快大面板的研发,并开展更多合作。

根据Berry的2018年度报告,其销售收入来自基因检测行业,包括基础研究服务,医疗检测服务,试剂销售和设备销售,以实现中下游行业的全面覆盖。

高阳在接受媒体采访时表示,癌症领域只是基因检测领域的下一个市场,而贝瑞基因肿瘤业务的核心地位是早期诊断,这是基因检测中最有价值的应用。在癌症领域,但目前这个市场还不成熟,临床应用侧重于晚期患者的精确治疗方案。

According to Piper Jaffray, a well-known investment bank, by 2026, liquid biopsy with genetic testing technology as the core will reach a global market size of $32.6 billion, including $28.6 billion in cancer and $2 billion in non-invasive prenatal diagnosis (NIPT).

This will mean that the market for genetic testing in the field of tumors is more than ten times larger than that of NIPT. According to this ratio, as the NextSeq CN500 breaks through the limitations of the NIPT field, it enters a wider range of applications such as tumor detection. Will achieve geometric growth.

xx